Appendectomy Colorectal Cancer Risk Cut 58%, Study Finds

New research on appendectomy colorectal cancer risk finds that patients who had their appendix removed for acute appendicitis developed colorectal cancer less often in later years than patients treated with antibiotics alone. The retrospective study found colorectal cancer in 0.7 percent of appendectomy patients versus 1.7 percent of those who received antibiotics only, a difference corresponding to a 58 percent lower relative risk in the surgery group.

The findings were selected by the Scientific Forum program committee for presentation at the congress, held in Washington from September 26 through September 29, as reported by Morocco Scribe, covering the American College of Surgeons Clinical Congress 2026. Researchers drew on the TriNetX Global Collaborative Network, a large international health database spanning 168 healthcare organizations, and matched patients by relevant characteristics to make the comparison as fair as possible.

The appendectomy colorectal cancer risk finding arrives as treatment for appendicitis itself is evolving. Antibiotics-only treatment has gained ground in recent years as an alternative to surgery for uncomplicated cases, sparing patients an operation. The new data adds a long-term dimension to that decision, and the appendectomy colorectal cancer risk findings give patients and surgeons one more factor to weigh.

Inside the numbers

After matching, each initial group contained 15,774 people with acute appendicitis who received either surgery or antibiotic treatment. Researchers then excluded patients with earlier colorectal cancer diagnoses, leaving 15,616 appendectomy patients and 15,295 antibiotic-treated patients in the final analysis. During follow-up, records showed 110 colorectal cancer cases after appendectomy and 254 cases after antibiotic-only treatment.

The appendectomy colorectal cancer risk gap persisted across the matched comparison, which is the study's main strength: by balancing the groups on relevant characteristics, the researchers reduced the chance that the difference simply reflects sicker patients getting one treatment over the other. The absolute rates were low in both groups, which matters for perspective. Even in the antibiotics group, fewer than 2 in 100 patients developed colorectal cancer during the study period.

Context from oncology helps frame the result. Colorectal cancer remains one of the most common cancers worldwide, and screening guidelines have been moving toward earlier colonoscopies as cases rise in younger adults. Any factor that meaningfully shifts long-term risk, even modestly in absolute terms, is worth understanding, because it could eventually inform both treatment guidelines and screening schedules.

Association is not proof: what doctors want you to know

The researchers behind the appendectomy colorectal cancer risk analysis urge caution on several fronts. The study identifies an association between treatment choice and later colorectal cancer diagnosis, but it does not establish that appendix removal prevents colorectal cancer. Retrospective database studies can show patterns, yet they cannot fully rule out unmeasured differences between the groups, and no medical journal has yet peer-reviewed this work.

There are also plausible biological explanations that need testing before anyone draws clinical conclusions. The appendix has been increasingly recognized as a reservoir for gut bacteria and a player in immune function, so its removal could plausibly alter the microbiome or inflammation in ways that affect cancer risk. Alternatively, the antibiotics themselves, or the recurrent inflammation in patients who avoid surgery, could be the real driver. The study cannot distinguish between these mechanisms.

Medical guidance has not changed. Doctors emphasize that nobody should seek an appendectomy to lower cancer risk based on a single conference abstract, and the decision between surgery and antibiotics for appendicitis should still rest on the severity of the case, the patient's overall health, and a surgeon's judgment. What the appendectomy colorectal cancer risk study does justify is more research, ideally prospective studies that track patients forward in time and dig into the biology.

Why it matters

The appendectomy colorectal cancer risk study is a classic example of how modern health data can surface surprising connections hiding in millions of medical records. For Gen Z readers, the takeaway is not to fear antibiotics or romanticize surgery. It is that treatment decisions have long tails, that big databases are rewriting what medicine knows, and that staying current with screening, especially as colorectal cancer rises in younger adults, remains the most proven way to protect yourself. Interesting associations deserve follow-up, not panic. Related coverage: diabetes remission study: 54% beat early-onset T2D with diet and the ADHD-gut connection.